Analysis of Free Drug Content in Antibody-Drug Conjugate Using 2D-LC/Q-TOF/MS

Significance of the Topic

Antibody-drug conjugates (ADCs) represent a rapidly growing class of targeted cancer therapies, combining the specificity of antibodies with potent cytotoxic agents.
Accurate quantification of unbound drug moieties is critical to ensure safety and efficacy, since residual free drug can increase off-target toxicity and compromise critical quality attributes.

Objectives and Study Overview

The study aimed to develop and validate an automated two-dimensional liquid chromatography coupled to quadrupole time-of-flight mass spectrometry (2D-LC/Q-TOF/MS) method for measuring free drug content in ADCs.
Key goals included integrating protein removal into the chromatographic workflow, improving throughput, and achieving high-accuracy identification of drug and linker-drug species.

Methodology and Instrumentation

Sample Preparation:

• Desalting and buffer exchange of ADC into 100 mM ammonium acetate (pH 7.0) at 5 mg/mL.
• Spike-in of DM1 and SMCC-DM1 standards at 100 µg/mL each.

Chromatographic Configuration:

• First Dimension (SEC): AdvanceBio SEC column with 100 mM ammonium acetate/40% ACN isocratic elution at 0.25 mL/min, UV detection at 252 nm.
• Heart-cutting mode transfers selected protein-free fractions into second dimension.
• Second Dimension (RP-LC): Poroshell EC-C18 column, gradient from 38% to 65% organic modifier over 5 min at 0.5 mL/min.

Mass Spectrometry:

• Agilent 6545XT AdvanceBio LC/Q-TOF with Jet Stream ESI in positive mode.
• Source conditions: 300 °C drying gas, 350 °C sheath gas, 3,500 V capillary voltage.
• Acquisition range m/z 100–1,700 at 1 spectra/s.

Main Results and Discussion

Organic Modifier Optimization:

• SEC scouting from 20% to 40% ACN identified 40% as optimal for sharp DM1 peaks while maintaining column integrity.

Heart-cutting Efficiency:

• Protocol captured three sequential fractions of the first-dimension peak between 8 and 10 min using multi-inject loops, enabling a total run time of 17 min.

2D-LC/MS Separation:

• UV and TIC chromatograms resolved three distinct peaks corresponding to DM1 and SMCC-DM1 diastereomers.
• Peak 1 (DM1): [M+H]+ at m/z 738.2839, mass accuracy 2.30 ppm.
• Peaks 2 and 2′ (SMCC-DM1 diastereomers): [M+H]+ at m/z 1072.3985, mass accuracy 0.18 ppm.
• Salt adducts and water losses were observed, attributed to buffer components and in-source fragmentation.

Benefits and Practical Applications

• Fully automated integration of desalting and protein removal protects the RP column and reduces manual steps.
• High-resolution MS detection ensures unambiguous identification of free drug and linker-drug species.
• Streamlined workflow reduces analysis time and increases laboratory throughput.
• Method can be readily adapted for quality control and regulatory compliance in biopharmaceutical development.

Future Trends and Potential Applications

• Expansion to other ADC payloads and linkers using tailored multi-dimensional approaches.
• Integration with high-throughput automation platforms and real-time data analysis tools.
• Application of machine learning for chromatographic method optimization and spectral deconvolution.
• Development of microflow 2D-LC systems to further reduce solvent consumption and increase sensitivity.

Conclusion

The presented 2D-LC/Q-TOF/MS method offers a robust, automated solution for quantifying free drug content in ADCs.
By combining SEC-based protein removal with RP separation and high-resolution mass detection, the workflow ensures rapid and accurate measurement of residual toxins, supporting safer and more effective ADC development.

Reference

• Li Y, et al. Limiting degradation of reactive antibody drug conjugate intermediates in HPLC method development. Journal of Pharmaceutical and Biomedical Analysis. 2014;92:114–118.
• Agilent Technologies. Application Note 5994-7182EN: Automated 2D-LC/Q-TOF/MS analysis of ADC free drug content.
• Singh R, et al. A new triglycyl peptide linker for antibody–drug conjugates with improved targeted killing of cancer cells. Molecular Cancer Therapeutics. 2016;15(6):1311–1320.